AIDS vaccines inch closer to useful existence.
Goldsmith
M F
MF
D016915:AIDS Vaccines; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000818:Animals; D002986:Clinical Trials as Topic; D015488:HIV Antigens / Q000302:isolation & purification; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D010455:Peptides / Q000302:isolation & purification; D015164:Vaccines, Inactivated / Q000302:isolation & purification; D014614:Vaccines, Synthetic / Q000302:isolation & purification; D014758:Viral Core Proteins / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000302:isolation & purification*; D054301:gag Gene Products, Human Immunodeficiency Virus
D016915:AIDS Vaccines; C052407:HGP-30 peptide, Human immunodeficiency virus-1; D015488:HIV Antigens; C067702:HIVAC-1e; D010455:Peptides; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic; C053473:VaxSyn HIV-1 (gp160) vaccine; D014758:Viral Core Proteins; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; D054301:gag Gene Products, Human Immunodeficiency Virus